Edwards Lifesciences (EW) PT Raised to $130 at Stifel; Reiterates Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Edwards Lifesciences Reports Second Quarter Results
July 26, 2017 4:15 PM EDTIRVINE, Calif., July 26, 2017 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended June 30, 2017.Â
Second Quarter and Recent Highlights:
Sales grew 11 percent to $842 million; underlying1 sales increased 15 percent to $864 million Global THVT sales grew 16 percent to $488 million; underlying sales increased 23 percent U.S. THVT sales grew 28 percent to $316 million EPS was $0.86, an increase of 48 percent; adjusted2... More